Radiographs of the hands and feet were normal. There were slight erosions of the sacroiliac joints and of the symphysis pubis.

The patient was treated with non-steroidal anti-inflammatory drugs (NSAIDs) and on several occasions with local injections of corticosteroids into the knee joints. For the psoriatic nails he took acitretine (Neotigason) 0.5 g daily to 2 g daily, in addition to NSAIDs.

The nail lesions did not improve. In view of the persisting arthritis, the patient has been treated since January 2000 with sulfasalazine (the dose being progressively increased from 0.5 g daily to 2 g daily), in addition to NSAIDs. Three months later, the nail lesions started to recede and they disappeared progressively (fig. 1B); the improvement has persisted until now. Concomitantly, there was a marked improvement of the arthritis.

Discussion

Nail disease is significantly associated with PsA. It is particularly common in cases with DIP joint involvement and tends to indicate more severe PsA. In view of the close chronologic relationship between the administration of sulfasalazine and the improvement of the nail lesions, it can be considered that sulfasalazine played a beneficial part in the pathologic condition of our patient. Dermatological assessment and treatment of patients with sulfasalazine for PsA has been reported in two series; according to the report published in the series of Gupta et al, patients treated with sulfasalazine for PsA showed signs of cutaneous improvement compared with those receiving placebo.

The series of Farr et al reports improved cutaneous lesions in as few as 3/15 patients treated with sulfasalazine and 1/15 patients receiving placebo. However, we could not find any indication of the evolution of possible simultaneous psoriatic nail lesions.

Treatment of PsA with cyclosporin or etanercept is effective for both joint and skin lesions of PsA.

5 Chikui T, Yonetsu K, Nakamura T

Nail lesions in psoriatic arthritis: recovery with sulfasalazine treatment

Treatment with sulfasalazine has been reported to be effective in psoriatic arthritis (PsA). However, the role of sulfasalazine in cutaneous lesions has been surrounded by controversies. As far as we know its possible beneficial effect on nail lesions has not been reported.

Case report

A 25 year old man had presented with nail lesions considered to be psoriatic since 1996. During the same period he started to have pain in both knee joints. Since 1998 he had also had pain in the distal interphalangeal (DIP) joints. At the end of the same year the patient consulted a rheumatologist. On clinical examination, both knee joints were swollen and a Baker’s cyst was present at the right side. The 4th and 5th DIP joints of both hands were red, painful, and slightly swollen. Nail deformities were present in both hands (fig.1A) and feet. Psoriatic lesions of the auditory canals and intergluteal fold were seen, prompting the diagnosis of psoriasis partime inversa.

Synovial fluid from the right knee joint contained 17.8x10^6 leucocytes (86% polymorphonuclear); no crystals were seen. The erythrocyte sedimentation rate was 33 mm/1st h. Rheumatoid factor was negative, as were cultures of nail specimens for fungi.

J C Gerster
Service de Rhumatologie, Médecine Physique et Réhabilitation, Centre Hospitalier, Université Vaudoise (CHUV), 1011 Lausanne, Switzerland; Jean-Charles.Gerster@chuv.hospvd.ch
muscular deficit, etc.), which explains the difference between the two evaluations. Cases where the IV immunoglobulin resulted in a reduced use of corticosteroids, or cases where IV immunoglobulins made it possible to avoid using immunosuppressive drugs were regarded as a success by the senior doctor, whereas patients did not necessarily have the same impression.

The 23 patients (77%) who said they had benefited from the IV immunoglobulin treatments at home gave the following reasons: better comfort (n=12), presence of next of kin (n=10), more occupation (n=6), better mood (n=3), maintaining activities (n=3), avoiding repeated trips to the hospital (n=5), better quality of sleep (n=2), better food (n=2). The seven patients (23%) who preferred the treatments at the hospital gave the following reasons: better monitoring, less trouble (IV immunoglobulin collected at the hospital pharmacy, calling the nurse at home, collection of tubes, needles, and perfusion stand at the pharmacy and at home).

The mean cost of a treatment in hospital was $2701 against $2471 for a treatment at home. The difference seems to be modest, yet for the 277 treatments performed at home over five years, the savings for the community amount to $63 691 with $85 377 of budget revenues for the past five years (table 1).

In the light of our experience and published reports of side effects, we propose some guidelines for home IV immunoglobulin infusion for patients with autoimmune disease (table 2). This procedure is appreciated by the patients and medical board and contributes to balancing the expenses for the National Health System.

Acknowledgments
To Monique Tomezak who typed this document; Thomas Rémy, Bernard Davergne, and Mazen Elaissi (Laboratoire français du fractionnement et des biotechnologies, 3 avenue des Tropiques, BP 305, Les Ulis, 91958 Courtaboeuf cedex) who helped us with the technical aspect of this study.

E Hachulla, A Wibaux, P-Y Hatron, U Michon-Pasturel, V Queyrel, A-L Fauchais, B Devulder
Internal Medicine Department, Hôpital Claude Huriez, University of Lille, 59037 Lille cedex, France
M-N Lefebvre, M Yilmaz
Central Pharmacy, University of Lille

References

Elastofibroma dorsi
Elastofibroma is a rarely diagnosed benign fibroproliferative lesion which occurs most commonly in the periscapular region of middle aged to elderly women. Recognition of the lesion is important as the differential diagnosis includes other benign and also

Table 1: Evaluation of the cost of at home IV immunoglobulin treatments (n=277) and comparison with the theoretical cost in hospital

<table>
<thead>
<tr>
<th>IV immunoglobulin</th>
<th>24 h hospital stay with hospital lump sum</th>
<th>Total cost for 277 treatments</th>
<th>Savings achieved for 277 treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Theoretical cost in hospital</td>
<td>$2705</td>
<td>$748274</td>
<td>$580556</td>
</tr>
<tr>
<td>(deduction on drug budget)</td>
<td>$605</td>
<td>$41</td>
<td>0</td>
</tr>
<tr>
<td>Effective cost at home</td>
<td>$2363</td>
<td>$684588</td>
<td>$63691</td>
</tr>
<tr>
<td>(15% of retrocession overcost*)</td>
<td>0</td>
<td>$67</td>
<td></td>
</tr>
<tr>
<td>Cost for one treatment in hospital : $2701</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost for one treatment at home: $2471</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*In France when a drug is retroceded by a hospital pharmacy, it is invoiced 15% higher, the difference being paid to the hospital administration to cover the management and traceability costs.

Table 2: Home IV immunoglobulin infusion guidelines for patients with autoimmune disease

1. Need for a defined diagnosis
2. Presence of rational physiopathological basis that could “legitimise” the use of IV immunoglobulin
3. Senior hospital prescription
4. Respect of the contraindication of home IV immunoglobulin programme: coronaryopathy, insufficiency or ischaemic cardiopathy, recent stroke, nephropathy, uncontrolled hypertension, thrombosis of the perfused vein, hypersensibility reaction after the first or second hospital infusion
5. More than one hospital based infusion before infusion at home to assess the tolerance
6. Average flow rate of IV immunoglobulin no quicker than 10 g per two hours
7. Collaboration with a home care organisation for visiting nurses and for collection of tubing and used bottles